Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

expansion

expansion is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 16
News articles 0
Drug details — expansion
Class
—
Route
—
Patents
20
Programs
16
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

expansion is an FDA-listed pharmaceutical active ingredient.

Key facts

INN expansion

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 2023/3668 Phase 2 · George Institute for · Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-lo
  2. 223050 Phase 2 · GSK Glaxo Smith · Neoplasms, Prostate
  3. BB-1701-G000-205 Phase 2 · Eisai · HER2 positive or HER2-low metastatic breast cancer
  4. CLIN-01194-450 Phase 2 · Ipsen · Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Sq
  5. CRN09682-191 Phase 2 · Anaxis Pharma · Metastatic or locally advanced SST2-positive neuroendocrine
  6. CSET 2022-3571 Phase 2 · George Institute for · Patients with hormone-receptor negative and HER2-negative (I
  7. LB101-101 Phase 2 · Centessa Pharmaceuticals · Advanced solid tumors
  8. TG1-CL-301 Phase 2 · Anaxis Pharma · Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombo

Related patents

Browse patents

  1. US 12343380

    Expansion of TILs utilizing AKT pathways inhibitors

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12031157

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12024718

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11981921

    TIL expansion processes using specific cytokine combinations and/or AKTi treatment

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11866688

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11667890

    Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11401506

    Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11384337

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11357841

    Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10760076

    Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10709812

    Biodegradable hydrogel for tissue expansion

    Expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10415015

    Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

    Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. CA 3091946

    EXPANSION ET DIFFERENCIATION DE CELLULES SOUCHES

    Expires Thu Sep 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9801911

    Expansion of alloantigen-reactive regulatory T cells

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9700583

    Methods and compositions for optimized expansion and implantation of mesenchymal stem cells

    Expires Mon Jul 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9095562

    Methods and compositions for optimized expansion and implantation of mesenchymal stem cells

    Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7368106

    Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state

    Expires Mon May 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7175838

    Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state

    Expires Mon Feb 08 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 6642049

    Human brain endothelial cells and growth medium and method for expansion of primitive CD34+CD38-bone marrow stem cells

    Expires Mon Oct 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  20. US 6291652

    Antibodies specific for proteins having polyglutamine expansions

    Expires Mon Sep 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is expansion?

expansion is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.